GlassScriptPhysician profile
Bradley W Rupp
NPI 1710953518
$3,245.16
in general payments reported to CMS, 2019-2025
37 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $514 · 2021: $840 · 2022: $525 · 2023: $365 · 2024: $409 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $651.36 | 2019-2024 | Xtandi |
| Abbvie INC. | $341.19 | 2019-2025 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $191.96 | 2020-2025 | Prolaris |
| Urovant Sciences INC | $180.61 | 2021-2022 | |
| Teleflex LLC | $173.19 | 2021-2025 | Barrigel, Urolift |
| Sumitomo Pharma America, INC. | $170.79 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $164.78 | 2019-2024 | |
| Urogen Pharma, INC. | $119.39 | 2020-2025 | Jelmyto |
| Tolmar Pharmaceuticals, INC. | $115.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $113.56 | 2023-2025 | Keytruda, Lynparza, Bridion |
| Kowa Pharmaceuticals America, INC. | $100.75 | 2022-2023 | Seglentis |
| Janssen Biotech, INC. | $92.75 | 2019-2024 | Erleada, Akeega, Balversa |
| Endo Pharmaceuticals INC. | $92.30 | 2021-2024 | Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $70.23 | 2020-2022 | |
| Immunitybio, INC. | $66.21 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $53.80 | 2022-2025 | Aquabeam Robotic System |
| Caldera Medical, INC | $45.50 | 2021 | |
| Myovant Sciences INC. | $43.45 | 2021 | |
| Olympus America INC. | $40.35 | 2022-2025 | Itind System |
| Accord Healthcare, INC. | $40.33 | 2023-2025 | |
| Kerecis Limited | $39.64 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Antares Pharma, INC. | $38.51 | 2022 | |
| Convatec INC. | $34.97 | 2021-2024 | |
| Davol INC. | $33.35 | 2020 | |
| Blue Earth Diagnostics | $27.25 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $22.74 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Novartis Pharmaceuticals Corporation | $22.57 | 2022 | |
| Ambu INC. | $21.47 | 2024 | |
| Neotract INC. | $20.64 | 2020 | |
| Genzyme Corporation | $18.48 | 2021 | |
| Rochester Medical Corporation | $17.55 | 2021 | |
| Progenics Pharmaceuticals, INC. | $15.93 | 2021 | |
| Axonics, INC. | $14.83 | 2022 | |
| Karl Storz Endoscopy-America | $14.09 | 2019 | |
| Medtronic, INC. | $12.69 | 2023 | Interstim |
| Ferring Pharmaceuticals INC. | $11.52 | 2019 | |
| Bard Access Systems, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.